Róbert Wessman-led Aztiq And Innobic Join Forces In $475m Acquisition Of Lotus Pharmaceutical And Adalvo To Create A Global Pharmaceutical Powerhouse

Release date:

– The Aztiq-Innobic consortium will obtain a 100%stake in Alvogen Emerging Markets Holdings Limited, therefore ending up being the leading investors in Lotus Pharmaceutical and the sole investor in Adalvo

REYKJAVÍK, Iceland, Nov. 26, 2021/ PRNewswire/– Aztiq(” Aztiq”), a health care financier led by Alvogen Creator and Chairman Róbert Wessman, and Innobic (Asia) Business Limited (” Innobic”), a life sciences subsidiary of Thailand commercial group PTT, today revealed the finalizing of a conclusive contract to obtain a 100%stake in Alvogen Emerging Market Holdings Limited (” AEMH”) from its existing investors for $475 million The objective of the alliance in between Aztiq and Innobic and the deal is to develop an effective pharmaceuticals business with worldwide resources, networks and reach.

Through the deal, among the biggest in the sector this year, the consortium ends up being the prominent investor in the international oncology pharmaceutical business Lotus Pharmaceutical (” Lotus”, TWSE ticker: 1795), and the sole investor in Alvogen Malta Holding Ltd., the owner of the fast-growing international organization to company (B2B) pharmaceutical business Adalvo.

AEMH is presently owned by Alvogen Lux Holdings Sarl (” Alvogen”). Secret investors in Alvogen consist of CVC Capital Partners and Temasek Holdings of Singapore, along with Aztiq. Alvogen will stay a prominent investor in the generic pharmaceutical business Alvogen United States, consisting of specialized pharma business Almatica, along with the 2nd biggest investor in worldwide biosimilars business Alvotech.


The members of the consortium bring outstanding and complementary management and competence. Róbert Wessman has more than the last 6 years effectively led the change of Lotus from a little regional Taiwanese business into a leading generic ora oncology business. Innobic’s moms and dad business PTT Group is Thailand’s biggest commercial corporation, with comprehensive business and company networks throughout the fast-growing ASEAN nations.

Aztiq’s creator and chairman, Róbert Wessman, will continue to function as chairman of the board of both Lotus and Adalvo.

This consortium’s special market understanding together with strong assistance from investors will offer Lotus and Adalvo with a competitive benefit in a prospering market, allowing them to extend their management internationally. Both business share the objective of making top quality medications available to clients all over the world, and with the competence and resources that will be easily offered to them, they will speed up development towards this objective. From oral oncology to research study development in over the counter items, Lotus and Adalvo will together lead the way for higher international access to first-rate treatments and medication.

Róbert Wessman, chairman and CEO of Alvogen and creator of Aztiq, commented: “I am really happy to have actually experienced the maturation of both Lotus and Adalvo. I wish to take this chance to thank the existing investors for their fantastic assistance in the change of both Lotus and Adalvo, and at the very same time to invite our brand-new partner Innobic as we eagerly anticipate performing the vital work of broadening access to medications to more individuals who require them. With our huge cumulative proficiency, and the thorough geographical networks and strong market intelligence in ASEAN brought by innobic and PTT, I think that Lotus and Adalvo will have an engaging competitive benefit, allowing both business to support one another and advance their international management in their sectors.”

Dr. Buranin Rattanasombat, senior executive vice president, development and brand-new endeavors, PTT and chairman of Innobic ( Asia), commented: This collaboration will accelerate our objective and allow Innobic to jump into being a completely incorporated pharmaceutical business. By being the significant investor in Lotus Pharmaceutical collectively with Aztiq, Innobic will have access to the ability of running a complete suite of pharmaceutical organization with a main concentrate on generic in numerous crucial illness locations, specifically oncology and neurological illness. This financial investment, together with the worldwide networks of Adalvo, will enhance access to high quality medications in area and is a significant turning point for our life sciences organization and its objective to advance public health and the pharmaceutical market in Thailand and the area.”


Tomas Ekman, Director of the Board, Alvogen Lux, commented: ” After 7 years as the lead investor of Lotus and the wider Asian organization, Alvogen concluded that now is the correct time to monetize our financial investment and letting Aztiq and Innobic continue the journey Lotus is on. Both Adalvo and Lotus will continue to team up carefully with the Alvogen group of business. Today’s statement follows Alvogen’s tactical focus and we mean to release the profits from the deal in line with our capital allotment top priorities to make the most of investor worth.”



About Aztiq


  • Aztiq is a long-lasting health care financier concentrated on pharmaceuticals, led by Alvogen creator and chairman Robert Wessman Moving forward, Aztiq will be functioning as a specialized pharmaceutical fund consultant and supervisor investing in numerous pharmaceutical possessions.
  • Aztiq’s investor base includes specific financiers in addition to significant global mutual fund amongst whose biggest possessions are pharmaceuticals business Alvogen, Alvotech, Lotus, Almatica, Almaject and Adalvo.
  • Developed in 2009, Aztiq was established on the concept that everybody must can medication, despite their monetary ways.

Appropriate history


  • Alvogen got a bulk stake in Lotus in 2014 and ever since Lotus has actually progressed into a next-generation pharmaceuticals business concentrated on worldwide oncology, with direct market gain access to in more than 10 nations in Asia and a portfolio with worldwide into more than 130 markets.
  • Because 2018, Alvogen has actually developed Adalvo from an internal B2B platform into a different organization system concentrating on international markets. Adalvo has actually quickly accomplished exceptional development, with over 500 deals and a first-rate portfolio of 60 distinguished medications. It is presently among the fastest growing B2B pharmaceutical business worldwide, serving partners and clients in over 100 markets all over the world.

View initial material to download multimedia: https://www.prnewswire.com/news-releases/robert-wessman-led-aztiq-and-innobic-join-forces-in-475 m-acquisition-of-lotus-pharmaceutical-and-adalvo-to-create-a-global-pharmaceutical-powerhouse-301432295 html


SOURCE Aztiq Fjárfestingar ehf

Find Out More

Author: admin

Leave a Reply

Your email address will not be published. Required fields are marked *